AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid

Complete sequencing of the mouse pseudoautosomal region, the most rapidly evolving ‘chromosome’

Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models

Data from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Data from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Data from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Data from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Data from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Data from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning

Figure 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Figure 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Figure 2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Figure 2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Figure 3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Figure 3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2

Supplementary Data 1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Supplementary Data Figures and Legends from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary Data Figures and Legends from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Supplementary Data from PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in <i>ATM</i>-Deficient Tumors and Potent Synergy With PARP Inhibitors

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary Fig. S1 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S10 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S12 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S13 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S15 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S16 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S2 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S3 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S4 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S5 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S6 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S7 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S8 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Fig. S9 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 1 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 2 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 3 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 5 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 6 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure 6 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Figure from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Table 1 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Table 2 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Table 3 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Supplementary Table S1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Supplementary Table S2 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Supplementary Table S3 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

Supplementary Tables S1-S3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary Tables S1-S3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Supplementary Tables S1-S6 from Perivascular NOTCH3<sup>+</sup> Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy

Table 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Table 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

Table 2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2

The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature